1996
DOI: 10.1677/joe.0.1510401
|View full text |Cite
|
Sign up to set email alerts
|

The effect of epidermal growth factor on circulating levels of IGF and IGF-binding proteins in adult Goettingen minipigs

Abstract: It has recently been demonstrated that epidermal growth factor (EGF) administration to neonatal rodents causes growth retardation with concomitant reductions in circulation levels of IGF-I. We describe the effects of systemic EGF administration for 4 weeks on circulating levels of IGF-I and IGF-binding proteins (IGFBPs) and on thyroid hormones (tri-iodothyronine, T3; thyroxine, T4) in sexually mature pigs. Goettingen minipigs of either sex were treated with placebo (n = 5) or EGF (30 micrograms/kg per day, n =… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
6
0

Year Published

1996
1996
2016
2016

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 19 publications
2
6
0
Order By: Relevance
“…Interestingly, the well known anti-mitogenic action of TGF-β in myogenic and other types of cells in vitro is believed to be mediated in part by TGF-β-induced IGF-binding protein (IGFBP)-3, which inhibits IGF action (Oh, et al, 1995;Kamanga-Sollo et al, 2003). Similarly, EGF seems to suppress growth in vivo by regulating the expression of IGFBPs (Murray et al, 1993;Vinter-Jensen et al, 1996;Chan and Wong, 2000). Taken together, these reports suggest that systemic and/or local availabilities of IGF-I, TGF-β, and EGF may influence the postmortem muscle quality, which was the basis of the hypothesis of the present study.…”
Section: Discussionsupporting
confidence: 73%
“…Interestingly, the well known anti-mitogenic action of TGF-β in myogenic and other types of cells in vitro is believed to be mediated in part by TGF-β-induced IGF-binding protein (IGFBP)-3, which inhibits IGF action (Oh, et al, 1995;Kamanga-Sollo et al, 2003). Similarly, EGF seems to suppress growth in vivo by regulating the expression of IGFBPs (Murray et al, 1993;Vinter-Jensen et al, 1996;Chan and Wong, 2000). Taken together, these reports suggest that systemic and/or local availabilities of IGF-I, TGF-β, and EGF may influence the postmortem muscle quality, which was the basis of the hypothesis of the present study.…”
Section: Discussionsupporting
confidence: 73%
“…As discussed, downregulation of IGFBPs can occur at the transcriptional level or at the post-translational level (Vinter-Jensen et al 1996, Edmondson et al 1999, van Neck et al 2000, Ozawa et al 2004. Our data demonstrating reduced IGFBP-3 and -4 mRNA levels support a transcriptional regulatory mechanism.…”
Section: Discussionsupporting
confidence: 71%
“…Several in vivo studies have demonstrated the effects of EGF on IGFBPs. For example, a four-week treatment of Goettingen minipigs with EGF resulted in reduced serum IGFBP-3 and IGF-I, while circulating IGFBP-1, -2 and -4 were elevated (Vinter-Jensen et al 1996). Similarly, EGF treatment of neonatal rats resulted in elevated serum IGFBP-1 and -2 without altered IGFBP-3 or -4 levels (Murray et al 1993).…”
Section: Discussionmentioning
confidence: 99%
“…Due to the lack of plasma we were not able to measure thyroid hormones and catecholamines. However, previous studies have reported increased levels of circulating thyroid hormones in Göttingen minipigs [8]as well as in rats [Flyvbjerg and Vinter-Jensen, unpublished data] treated for 1–4 weeks with subcutaneously administered EGF. The effect in rats is most likely a stimulation of the pituitary as the circulating levels of thyroid-stimulating hormone increases.…”
Section: Discussionmentioning
confidence: 99%
“…When EGF is systemically administered it may bind to and activate the EGFr, which is also expressed in adipose tissue [5]. On systemic administration EGF may also influence other hormonal systems, thereby exerting indirect effects on adipose tissue [8]. …”
Section: Introductionmentioning
confidence: 99%